UMnyango Wezizwe Zonke

Ekuqaleni kukaMashi, i-National Medical Products Administration yavuma i-Jaypirca® (pirtobrutinib) yokwelapha iziguli ezindala ezine-chronic lymphocytic leukemia (CLL) noma i-small lymphocytic lymphoma (SLL) ezithole okungenani ukwelashwa okukodwa kwangaphambilini, okuhlanganisa ne-Bruton's tyrosin...Funda kabanzi»

Izindaba ezijabulisayo zisanda kuvela ku-Center for Drug Evaluation (CDE) ye-National Medical Products Administration yaseShayina: isivivinyo sezokwelapha se-KSD-101 Injection, esakhiwe yi-Hensen Bio, sivunyiwe. Ukusetshenziswa okubonisiwe kungokwe-"EBV-associated hematological tumors" ezi...Funda kabanzi»

Muva nje, i-China National Medical Products Administration (NMPA) ivumile inkomba entsha ye-Bireociclib, umuthi omusha we-Class 1 owakhiwe ngokuzimela yi-Xuanzhu Biopharmaceutical. Inkomba entsha iwukusetshenziswa kanye ne-aromatase inhibitor njengokwelashwa kokuqala kwe-endocrine...Funda kabanzi»

Ngomhlaka-28 kuNhlolanja 2026, i-National Medical Products Administration (NMPA) yavuma ngokusemthethweni ukudayiswa kwe-JMKX001899 sulfate yokwelapha iziguli ezindala ezine-KRAS G12C-mutated advanced non-small cell lung cancer (NSCLC) ezithole okungenani ukwelashwa okukodwa kwangaphambilini. I-JMKX00189...Funda kabanzi»

Ngomhlaka-13 kuNhlolanja 2026, i-Center for Drug Evaluation (CDE) ye-National Medical Products Administration yaseShayina yamemezela ukuthi amaphilisi e-GFH375 afakiwe ku-Breakthrough Therapy Designation yokwelapha iziguli ezine-KRAS G12D-mutant non-small cell lung cancer (NSCLC) ...Funda kabanzi»

Ngomhlaka-12 kuNhlolanja 2026, i-Center for Drug Evaluation (CDE) ye-National Medical Products Administration yaseShayina yamemezela ngomhlaka-4 kuNhlolanja ukuthi i-ENHERTU® (trastuzumab deruxtecan) iphakanyisiwe ukuthi ifakwe kuHlelo Lokwelapha Oluphuthumayo ukuze isetshenziswe njengokwelashwa okusizayo ezigulini ezindala ezine-HER2...Funda kabanzi»

UMnyango Wezizwe Ngezizwe Wesibhedlela i-Beijing South Region Oncology Hospital uyaziqhenya ngokunikeza iziguli zamazwe ngamazwe ukufinyelela ekwelashweni komdlavuza okuseqophelweni eliphezulu, okuhlanganisa ne-Boron Neutron Capture Therapy (BNCT) – ukwelashwa okusha osekushintshe izimpilo kakade. Ubufakazi Bangempela: Uhambo LukaNkk. Wu Ngo-2022...Funda kabanzi»

Ngomhlaka-9 kuNhlolanja 2026, iwebhusayithi esemthethweni ye-Center for Drug Evaluation (CDE) ye-National Medical Products Administration (NMPA) yamemezela ukuthi i-ZL-1310 yokujova, i-DLL3-targeting antibody-drug conjugate (ADC) entsha, ihlelwe ukuthi inikezwe i-Breakthrough Therapy Designation. Njengelungu...Funda kabanzi»

Kuwo wonke umuntu ohamba ibanga elide ukuyofuna ukunakekelwa kwethu, siyaqonda ngokujulile: lokho okulethayo akugcini nje ngokuba amarekhodi ezokwelapha ayinkimbinkimbi kodwa futhi nokwethembana nethemba lomndeni wakho wonke. E-Beijing South Region Oncology Hospital International Department, sibona izindaba ezinjalo nsuku zonke—ho...Funda kabanzi»

Njengoba sibhekene nenselele yokwelashwa komdlavuza we-colonectal one-HER2-positive, siyaqonda ngokugcwele isifiso sakho esiphuthumayo sezinketho zokwelapha ezisebenza kahle nezithuthukisiwe. Namuhla, siletha izindaba ezinkulu ezikhuthazayo ezivela ensimini ye-oncology yaseShayina. **Ukwelashwa Okuphumelelayo Kuseduzane: I-SHR-A1811 Ibonisa Ukungafani...Funda kabanzi»

Muva nje, i-National Medical Products Administration yaseShayina ivumile ngokusemthethweni ukwelashwa okuhlanganisiwe kwe-Anlotinib Hydrochloride kanye ne-Penpulimab yi-Chia Tai Tianqing ekwelapheni kokuqala kwe-carcinoma yesibindi ethuthukisiwe. Lokhu kuphawula isibonakaliso seshumi esivunyelwe se-Anlotinib Hyd...Funda kabanzi»

Muva nje, insimu yokwelashwa komdlavuza eShayina ifinyelele ingqophamlando ebalulekile. Ngomhlaka-7 Januwari 2025, i-National Medical Products Administration yagunyaza ngokusemthethweni umuthi omusha i-SHR-1701 ukuthi usetshenziswe emakethe. Ukhonjiswa ngokuhlanganiswa ne-chemotherapy njengokwelashwa kokuqala kwe-l...Funda kabanzi»